It Seems Esperion Therapeutics Inc (NASDAQ:ESPR) Will Go Down. Just Reported More Shorted Shares

May 26, 2018 - By Vivian Park

Investors sentiment decreased to 1.33 in 2017 Q4. Its down 0.34, from 1.67 in 2017Q3. It is negative, as 19 investors sold Esperion Therapeutics, Inc. shares while 39 reduced holdings. 33 funds opened positions while 44 raised stakes. 22.69 million shares or 0.18% less from 22.73 million shares in 2017Q3 were reported.
1,689 were accumulated by Gilder Gagnon Howe And Co Limited Liability. Gru One Trading Lp holds 0% or 4,841 shares. Principal Financial Gru has invested 0% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Discovery Capital Ltd Limited Liability Company Ct stated it has 475,175 shares or 0.97% of all its holdings. State Bank Of Montreal Can holds 7,596 shares. 8,394 are owned by Tiverton Asset Mngmt Limited Liability. Bnp Paribas Arbitrage owns 3,599 shares for 0% of their portfolio. Geode Capital Ltd Liability Corp has 174,080 shares. North Star Invest Management Corp has invested 0% of its portfolio in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Perigon Wealth Lc holds 0.04% or 1,657 shares. Partner Inv Management Limited Partnership holds 12,140 shares or 0.92% of its portfolio. Weiss Asset Mngmt Lp reported 5,427 shares or 0.03% of all its holdings. C Group Incorporated A S owns 4,433 shares or 0% of their US portfolio. Hamilton Lane Advisors Limited Liability Com accumulated 115,344 shares or 3.92% of the stock. 10,456 were accumulated by D E Shaw And Co Inc.

The stock of Esperion Therapeutics Inc (NASDAQ:ESPR) registered an increase of 13.87% in short interest. ESPR’s total short interest was 3.94M shares in May as published by FINRA. Its up 13.87% from 3.46M shares, reported previously. With 399,000 shares average volume, it will take short sellers 10 days to cover their ESPR’s short positions. The short interest to Esperion Therapeutics Inc’s float is 18.57%.

The stock decreased 0.40% or $0.15 during the last trading session, reaching $37.54. About 714,934 shares traded. Esperion Therapeutics, Inc. (NASDAQ:ESPR) has risen 89.86% since May 26, 2017 and is uptrending. It has outperformed by 78.31% the S&P500.

Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol . The company has market cap of $1.01 billion. The Company’s lead product candidate is Bempedoic acid, an inhibitor of ATP-citrate lyase that reduces cholesterol biosynthesis that is in Phase III long-term safety and tolerability study. It currently has negative earnings.

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Ratings Coverage

Among 14 analysts covering Esperion (NASDAQ:ESPR), 8 have Buy rating, 3 Sell and 3 Hold. Therefore 57% are positive. Esperion had 21 analyst reports since December 5, 2017 according to SRatingsIntel. The stock has “Underperform” rating by Bank of America on Wednesday, May 2. The firm has “Buy” rating given on Thursday, December 14 by Needham. The rating was maintained by Credit Suisse with “Outperform” on Friday, May 4. The rating was maintained by Jefferies with “Buy” on Monday, March 19. Cowen & Co maintained Esperion Therapeutics, Inc. (NASDAQ:ESPR) rating on Wednesday, March 7. Cowen & Co has “Buy” rating and $95.0 target. The stock has “Neutral” rating by UBS on Wednesday, February 21. The rating was maintained by Stifel Nicolaus with “Buy” on Monday, January 15. The firm earned “Buy” rating on Friday, January 5 by Bank of America. The stock has “Sell” rating by J.P. Morgan on Thursday, May 3. The rating was maintained by Northland Capital with “Buy” on Thursday, April 19.

More notable recent Esperion Therapeutics, Inc. (NASDAQ:ESPR) news were published by: which released: “Esperion Therapeutics halted pending news” on May 23, 2018, also with their article: “Here’s Why Esperion Therapeutics Inc. Stock Is Bouncing Back Today” published on May 04, 2018, published: “INVESTOR ALERT: Kirby McInerney LLP Advises Esperion Therapeutics, Inc. (ESPR) Investors of Potential Claims” on May 25, 2018. More interesting news about Esperion Therapeutics, Inc. (NASDAQ:ESPR) were released by: and their article: “Esperion Shares Plunge After Cholesterol-Lowering Drug’s Phase 3 Results Stir Safety Concerns” published on May 02, 2018 as well as‘s news article titled: “3 Top Healthcare Stocks to Buy Right Now” with publication date: May 01, 2018.

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: